Podcast
Galaxy Balance
Hosted by Cory Smith · EN
Galaxy Balance explores the frontier where biology, technology and consciousness meet. Each episode brings together pioneers shaping our collective future, from genome engineers and AI builders to longevity researchers, space explorers, and mindfulness practitioners. Hosted by Cory Smith, the conversations dive deep into how these seemingly distant fields form an interconnected ecosystem, one that balance innovation with introspection, science with spirit, and ambition with awareness. At its core, Galaxy Balance is about integration; the idea that our greatest leaps forward happen when disciplines collide. The same algorithms that decode galaxies can help us understand genomes; the same principles that govern consciousness can illuminate AI. Through long-form, unscripted dialogue, the show invites listeners to zoom out from the silos of specialization and see the larger pattern: a living system of intelligence evolving across scales – molecular, planetary, and cosmic.
20episodes
Episodes
Newest firstAll episodes
Charles Fracchia: Securing the Bioeconomy
1w ago01:02:54Tap to summarizeIn this episode of Galaxy Balance, I sit down with Charles Fracchia to explore the emerging infrastructure layer of synthetic biology. We discuss the future of secure and scalable bioengineering, the role of community laboratories in accelerating innovation, and how biology is evolving into a programmable technology platform. Charles shares the story behind BioBright, the creation of Bio-ISAC, and the broader challenge of building resilient systems for a world where genetic engineering becomes increasingly accessible.The conversation moves from cyberbiosecurity and open science to AI-driven biological design, scientific culture, and the growing overlap between software engineering and biotechnology. We also explore the long-term future of human enhancement, decentralized science, and how science fiction continues to shape the ambitions of the next generation of builders working at the frontier of biology.Timestamps:00:00 - Overcoming cynicism in AI's role in biosecurity00:40 - Introduction to Charles Fracchia and his pioneering work02:07 - Charles's background and journey into biotech innovation04:01 - Balancing classical education with trial-by-fire experience06:26 - AI as a search tool versus experimental center in biology08:28 - Developing AI systems for biological experiment automation11:35 - The founding and evolution of Black Mesa and its mission14:26 - The importance of digital batch records and AI-assisted QA QC16:06 - AI's role in drug development, safety, and traceability18:44 - Ensuring trust and integrity in AI models for biotech applications22:51 - Addressing data poisoning and ensuring model robustness24:45 - Strategies for verifying biological data integrity through cryptography and blockchain33:55 - Future threats like AI-driven bio weapons and safeguarding strategies42:48 - The importance of operational innovation in accelerating bioeconomy growth58:25 - Influence of science fiction on biosecurity and innovation60:11 - Advice for emerging scientists in a rapidly changing landscape1:02:53 - Closing remarks and future outlook from Charles Fracchia
Transcribe →Tyler Todt: Discipline Over Dopamine
3w ago00:53:12Tap to summarizeWhat if the most powerful form of human optimization has nothing to do with biotech?In this episode of Galaxy Balance, Cory sits down with Tyler Todt, who has built a platform around physical health, mental resilience, and intentional living. While the world races toward gene editing, AI, and synthetic biology, Tyler focuses on something more immediate: how daily habits, environment, and mindset shape the trajectory of your life.They explore the tension between technological enhancement and human discipline, from fertility and genetic selection to Neuralink and simulated realities. Along the way, Tyler shares how small, consistent changes transformed his health, marriage, and purpose, and why most people fail by trying to do too much at once.Timestamps:00:00 - Small diet tweaks for improved energy and health00:11 - The value of movement and daily habits in life optimization00:44 - Introducing Tyler Todt’s background and mission01:12 - Tyler’s journey from normal life to disciplined optimization02:17 - Marriage, weight gain, and mental health struggles in the journey03:08 - Creating intentional rules to improve life quality04:08 - Mindset shifts for sustainable health improvements04:45 - Challenges in maintaining motivation and overcoming setbacks05:02 - Tips for starting small and building routines06:01 - The neuroscience of habits and pattern creation07:27 - The importance of grace and balance in biohacking08:23 - Brain's autopilot and neural pathways in behavior change09:16 - Ethical debates around reproductive biotech advances09:43 - The use of stem cells in fertility and new treatments10:32 - The future of gene editing and embryo selection13:33 - Ethical considerations of genetic trait modification15:35 - The potential dangers of designer traits and societal impacts16:20 - Risks of focusing on narrow breeding goals16:49 - Natural genetic variation and evolutionary trade-offs17:09 - The double-edged sword of certain genetic traits like sickle cell18:16 - Limitations of current genetic understanding and AI's potential19:16 - Advances in DNA reading, writing, and CRISPR technology20:03 - The ethical dilemmas of germline modifications and human enhancement21:26 - The future of human evolution and the possibility of multiple iterations22:16 - Space exploration, colonization, and interstellar travel23:05 - The societal and ethical implications of AI-enhanced humans24:33 - Neural interfaces, Neuralink, and virtual reality futures25:35 - The allure and dangers of immersive digital worlds26:13 - The role of genuine human experiences versus synthetic life27:32 - The societal challenges of technological inequality28:02 - The quest for extraterrestrial life and the Fermi paradox39:15 - The potential for hidden advanced technologies and secret projects40:44 - The vastness of space and the search for alien life45:57 - Global cooperation and the importance of humanity's future46:55 - UFOs, alien encounters, and government disclosures49:40 - Living in a universe of uncertainties and existential risks50:14 - Science fiction recommendations: The Matrix and beyond50:53 - Advice for aspiring longevity explorers: control, curiosity, and consistency52:25 - Mental health, nervous system management, and daily reflection53:01 - Final thoughts and appreciation for innovative minds in health science
Transcribe →TJ Cradick: Building the Future of Genome Editing
May 1100:59:32Tap to summarizeGenome editing has moved from experimental concept to FDA approved medicine in less than a generation. Few people have been closer to that transformation than TJ Cradick.TJ was one of the earliest pioneers in programmable biology, helping shape the field from the era of zinc finger nucleases through the rise of CRISPR and next generation editing systems. As the second employee and Head of Genome Editing at CRISPR Therapeutics, he helped lay the scientific foundation for Casgevy, the first FDA approved CRISPR therapy. Later, at Excision BioTherapeutics, he worked on some of the first in vivo CRISPR therapies targeting latent HIV reservoirs.In this episode, we dive deep into the evolution of genome engineering. We explore the transition from protein engineered nucleases to scalable CRISPR guide libraries, and the growing importance of delivery technologies capable of targeting tissues beyond the liver. TJ explains how off target analysis evolved from primitive assays into massively parallel sequencing pipelines and why the future of gene editing depends just as much on delivery and manufacturing as the editing enzymes themselves.We also discuss the hidden challenges behind FDA approval, the realities of scaling genome editing therapies, the future of in vivo editing, and the ethical questions surrounding human germline engineering. This conversation is a rare look inside the engineering, regulation, and philosophy of one of the most transformative technologies humanity has ever developed.· 0:00 - Science Fiction to Science Fact· 0:23 - Cutting Edge of Science· 0:37 - Introduction to TJ Cradick· 1:06 - CRISPR Therapeutics and Beyond· 1:42 - Early Interest in Science· 2:12 - Academic Journey· 3:08 - Transition to Biotech· 4:04 - Zinc Finger Nucleases· 5:28 - Evolution of Screening Technologies· 6:48 - CRISPR Libraries and High Throughput Screens· 8:07 - New Technologies in Gene Editing· 9:15 - Off-Target Effects and Assays· 11:23 - Future Opportunities in Gene Editing· 13:18 - Regulatory Challenges· 16:24 - Cost Challenges in Genome Editing· 18:22 - Manufacturing and Delivery Innovations· 20:14 - Delivery Challenges and Innovations· 22:30 - Capsid Design and Blood-Brain Barrier· 24:01 - Viral vs. Non-Viral Delivery Systems· 27:19 - IP Limitations and CRISPR Variants· 30:31 - Target Selection for Therapeutics· 34:03 - Precise Repair Technologies· 37:03 - Off-Target Effects in Gene Editing· 42:31 - Genetic Instability in Edited Cells· 46:20 - Human Germline Engineering· 49:19 - CRISPR for Viral Cure· 51:27 - Regulatory Path Improvements· 54:20 - Balancing Speed and Safety· 57:03 - Advice for Future Scientists
Transcribe →Nabiha Saklayen: From Physics to Scalable Cell Therapies
Apr 2701:01:42Tap to summarizeWhat does it actually take to manufacture biology at scale?In this episode of Galaxy Balance, Cory Smith sits down with Nabiha Saklayen, CEO and co-founder of Cellino, to explore the future of cell therapy manufacturing. Trained in physics and biophotonics, Nabiha is applying principles from semiconductor fabrication to one of the hardest problems in medicine: turning powerful cell therapies into scalable, reliable products.The conversation dives into the core challenges of iPSC variability, autologous versus allogeneic strategies, and why manufacturing remains the primary bottleneck preventing these therapies from reaching patients. Nabiha explains Cellino’s approach, combining AI, imaging, and laser-based systems to create a closed, automated platform for cell production.They also explore how AI is reshaping biology, how scientists are evolving into computational operators, and what the future lab looks like as automation and intelligence converge. From Artemis missions to the arrow of time in reprogramming, this episode connects physics, biology, and the long-term future of engineered life.This is a deep look at the infrastructure layer of biofuturism and what must be true for living medicines to reach the world at scale.00:00 - The importance of curiosity and bold thinking in science and technology00:11 - Nabiha Saklayen’s background and childhood fascination with space02:01 - Her journey through physics, biophysics, and motivations behind her work03:24 - Early influences from diverse cultures and educational choices06:17 - How personal loss shaped her scientific focus on biomedicine08:40 - Insights on Artemis moon mission and space biology innovations12:27 - Inspiring the next generation: fostering curiosity in children14:20 - AI as a tool for biology and the significance of large language models17:03 - The origins of Cellino: applying light-based manufacturing methods20:22 - Cellino’s optical bioprocess and steps toward clinical-scale production22:23 - Addressing variability in iPSC reprogramming and quality control26:32 - Regulatory milestones and FDA collaborations in advanced therapies30:27 - The role of automation and dashboards in scalable cell manufacturing36:52 - Visualizing the process from donor cell to differentiated therapy40:35 - Maintaining sterility and process control in cell banking45:40 - How AI interfaces with robotics and the role of scientists in automated development46:04 - The physics of cell removal using bubbles and laser technology49:20 - How AI and machine learning optimize manufacturing processes and data management54:54 - Advice for students passionate about science and innovation57:19 - Future of human creativity and AI partnership in work and art59:05 - Speculating on the creation or existence of AGI and its first questions1:00:03 - The influence of science fiction on Nabiha’s worldview and recommended books
Transcribe →Noah Davidsohn: Engineering Longevity at the Genetic Level
Apr 2001:03:06Tap to summarizeWhat if aging is not a collection of diseases, but a system-level failure we can intervene in?In this episode of Galaxy Balance, Cory Smith sits down with Noah Davidsohn, co-founder and CSO of Rejuvenate Bio, to explore a new approach to longevity rooted in gene therapy and systems biology.Noah’s work focuses on treating aging at its source by rebalancing key biological pathways across the body. Instead of targeting one disease at a time, his team is developing combination gene therapies designed to improve function across multiple organs simultaneously.Rejuvenate Bio is currently raising on Wefunder. This is a rare opportunity to invest in a scaling biotech on the same terms as their VC partners. If our conversation resonated with you, this is your chance to join what Dr. Noah Davidsohn is building. Learn more and invest at wefunder.com/rejuvenatebio00:00 - Replacing organs to reverse aging: science fiction or imminent reality00:34 - Welcome to Galaxy Balance: exploring biology and AI frontiers01:01 - Noah Davidson’s background and mission at Rejuvenate Bio01:57 - Reprogramming biological systems for systemic healthspan extension02:41 - The influence of sci-fi on Noah’s interest in space and longevity03:38 - Space exploration's crossover with biological resilience05:25 - The societal impact of science fiction on technological progress07:55 - Addressing dystopian themes in modern sci-fi and their societal reflection08:16 - The absence of longevity-focused sci-fi and Noah’s motivation09:12 - Personal story: pet dog inspired Noah’s longevity work10:33 - Origin of Rejuvenate Bio and its mission to treat aging11:57 - Combining gene therapies targeting multiple age-related diseases13:44 - The potential and limitations of epigenetic partial reprogramming14:14 - Upcoming clinical trials and safety considerations for gene therapy16:01 - Cyclic gene therapy and risks of permanent expression17:43 - Inducible gene expression systems: safety and practical considerations21:19 - Systemic, liver-targeted gene therapies: permanent vs. transient22:33 - Strategies for pet therapies and expanding to human applications25:47 - Manufacturing innovations reducing costs for wide-scale treatment27:12 - Prophylactic use of gene therapies in pets and humans29:08 - Targeting multiple diseases with a single systemic therapy30:40 - Breeds at risk for mitral valve disease and targeted therapy efforts33:42 - Disease-modifying treatments for fibrosis and heart failure36:48 - How AAV vector delivery works and safety measures in tissue targeting42:47 - Regulatory pathways for animal therapies and translational relevance44:22 - Challenges in funding and VC environment for longevity startups45:45 - The strategy of using animal models as a bridge to human therapies50:05 - Future scientific directions: partial reprogramming and cell replacement tech52:37 - The concept of longevity escape velocity and current progress53:44 - Personal longevity practices: exercise, diet, sleep, stress management55:27 - The role of biometric feedback devices in health monitoring56:54 - Emerging modalities and innovative approaches in anti-aging research58:24 - The ship of Theseus analogy for cell and tissue replacement59:37 - Philosophical questions about consciousness and identity in aging1:00:43 - Recommended sci-fi books for longevity and biotech enthusiasts1:01:39 - Career advice for aspiring scientists and interdisciplinary innovation1:02:45 - Wrap-up and best wishes for ongoing longevity breakthroughs
Transcribe →Tae Seok Moon: Engineering Biology at Planetary Scale
Apr 601:08:49Tap to summarizeSynthetic biology is entering a new phase where biology can be treated as an engineering discipline. In this episode of Galaxy Balance, Cory Smith speaks with Dr. Tae Seok Moon, professor at the J. Craig Venter Institute and a leader in synthetic biology, about the long arc from reading DNA to eventually designing biological systems from first principles.Tae shares his unconventional path into science. As a student in Korea he originally wanted to be a poet before choosing chemistry and engineering. that early philosophical curiosity about existence ultimately drew him toward biology and the story of life emerging from molecules after the Big Bang.The conversation explores the evolution of synthetic biology through a literary metaphor. DNA sequencing allowed scientists to read the letters of life. Genome synthesis made it possible to write those letters. Gene editing introduced a way to revise existing text. Moon argues that most of modern biotechnology still resembles editing or copying nature rather than true creative writing in biology. Only recently have tools such as AI-guided protein design begun to generate entirely new biological "words."Moon also discusses the legacy of Craig Venter and the creation of the first cell controlled by a synthetic genome. That milestone demonstrated that digital DNA stored in a computer can be turned back into a functioning biological system, a reversal of sequencing that points toward a future where genomes become programmable substrates.The episode then moves into Moon's work at the intersection of space exploration and biotechnology. His team demonstrated that bacteria can produce the antioxidant lycopene in simulated microgravity using resources that would be available on the Moon or Mars. The system converts plastic waste into a carbon source and processes nutrients derived from human waste to fuel microbial production, a concept aimed at enabling sustainable life support systems during long-duration space missions.Beyond space exploration, Moon leads global collaborations focused on transforming waste streams into useful chemicals and materials. He argues that the constraints of space missions mirror the resource challenges facing Earth today, from plastic pollution to carbon emissions. Technologies developed for closed-loop life support in space may also help build circular bioeconomies of Earth.The conversation also tackles the rapid rise of artificial intelligence in biology, the future of scientific publishing, and the challenge of maintaining human creativity in an era of AI-generated research and communication. Moon reflects on what may remain uniquely human: genuine motivation, emotion, and the drive that comes from purpose and connection.The episode closes with a story about one of Moon's former students who overcame severe adversity and later helped lead the development of a COVID vaccine. For Moon, that journey captures the deeper motivation behind science. The next generation of researchers will face immense challenges, but their work will shape the technologies that improve life across the planet.This episode explores the frontier where biology becomes designable, where microbes may help sustain human life beyond Earth, and where the language of DNA may one day evolve from editing nature to composing entirely new forms of life.0:00 - Introduction1:01 - Tae Seok Moon Background2:34 - From Poet to Scientist8:26 - DNA as Language & Creation12:37 - Synthetic Cells & Venter18:31 - Microbes in Space25:47 - ISS & Space Experiments29:22 - Closed Ecosystems Challenge32:25 - Solving Global Problems37:44 - Science Fiction Influence40:36 - AI in Synthetic Biology50:38 - Future of Scientific Publishing1:01:10 - Advice for Young Scientists
Transcribe →Pranam Chatterjee: Programming Life with AI
Mar 3001:01:00Tap to summarizeWhat if biology could be engineered the way we engineer software?In this episode of Galaxy Balance, I'm joined by Pranam Chatterjee, Assistant Professor at the University of Pennsylvania and leader of the Programmable Biology Group, working at the intersection of AI, synthetic biology, and next-generation therapeutics.Pranam's work is shaping a future where generative models can design peptides and biologics from sequence data alone, enabling a new era of programmable medicine.We explore how Pranam went from studying religion and philosophy to transferring into MIT and building cutting-edge computational tools for biology. We dive into his time in George Church's lab, where early computational strategies helped spark the origins of Gameto, and how that work evolved into today's iPSC-derived ovarian support cell technologies now entering clinical trials.From there, we go deep into the frontier of AI-driven molecular design:• Do we actually need protein structure to design effective therapeutics?• How do we optimize binding, toxicity, permeability, and immunogenicity simultaneously?• What does "virtual cell" really mean, and why does mapping cell states matter?• How close are we to "vibe coding biology," where natural language becomes the interface to biological engineering?We also discuss the future of automation, robotics, and agentic AI in biology, as well as the ethical risks of democratized generative models in biotech.This conversation is a window into the net phase of human capability: not just ready biology, but designing it.00:00 - Introduction to AI-driven therapeutic peptide design01:05 - Background of Pranam Chatterjee's journey from religion to science02:50 - The evolution of AI models in synthetic biology05:17 - Key milestones: from modeling to clinical applications like Gameto08:19 - The founding story of Gameto and major breakthroughs12:20 - Expanding into disease targeting and regenerative medicine17:50 - The shift to virtual cell and organism design22:16 - Tools for peptide design: Peptune and PEPMLM25:04 - Generative modeling with language models and functional constraints28:32 - Imagining programmable organisms and mythical creatures29:41 - Hardware importance and future of vibe-coded biology31:54 - The role of automation and robotics in biotech labs33:47 - Mentoring students for the AI-biotech revolution36:50 - Targeting rare diseases and regulatory considerations40:34 - Global competition, safety, and ethics in biotech innovation44:44 - Designing molecules with AI: from complexity to deliverability45:09 - Data needs: where to find diverse biological datasets47:49 - The rise of AI agents in scientific research50:12 - Ethical responsibilities in AI bioengineering52:38 - Safeguards against harmful biotech applications55:22 - Thoughts on artificial general intelligence and human purpose58:40 - How science fiction inspires biotech innovation1:00:13 - Book recommendations and closing thoughts
Transcribe →Jonathan Scheiman: Microbes of Elite Performance
Mar 2301:01:49Tap to summarizeIn this episode of Galaxy Balance, Cory Smith speaks with Dr. Jonathan Scheiman, co-founder and CEO of FitBiomics, about the science of elite performance, microbiome discovery, and the future of metabolic health.Jonathan shares his journey from Division I basketball player to biomedicine PhD and postdoctoral researcher in the Church Lab, where unconventional ideas are encouraged and ambitious biology is the normHis central question was simple but radical: instead of studying disease, what if we studied peak human performance?That question led to a longitudinal study of Boston Marathon runners, where his team collected microbiome samples before and after intense endurance events. The data revealed a striking pattern. One microorganism, Veillonella, spiked in abundance immediately after the marathonFurther analysis showed that this microbe uniquely metabolizes lactate and converts it into short-chain fatty acids such as propionateLactate is often misunderstood as a fatigue molecule. In reality, it is a normal metabolic fuel. When produced in excess during intense exercise, it accumulates in the bloodstream. Scheiman’s work suggests that a portion of circulating lactate is shuttled to the gut, where Veillonella uses it as a carbon source, producing metabolites that may support mitochondrial function, muscle recovery, glucose utilization, and anti-inflammatory pathwaysThe episode explores:• How elite athletes may represent a rare biological phenotype comparable in rarity to centenarians • Why the microbiome can shift rapidly in response to exercise intensity • The challenges of culturing and scaling strict anaerobic microbes for commercialization • The regulatory pathway differences between therapeutic microbiome interventions and consumer health products • How AI and machine learning enabled the discovery of novel microbial signals in complex datasetsThe conversation expands into longevity, mitochondrial efficiency, digital health integration, and the idea of FitBiomics as a biological data company rather than simply a probiotic brandScheiman also reflects on science fiction, pop culture, and storytelling as forces that shape technological ambition, drawing connections between Marvel, AI, and biotechnology innovationThis episode sits at the intersection of microbiome science, metabolic optimization, artificial intelligence, and the long-term future of human performance.If the biology of elite athletes can be decoded and translated, the implications extend far beyond sport. 00:00 - Introduction to microbiome insights for human performance02:20 - Personal journey from sports to biotech innovation05:28 - How elite athletes inspired microbiome research09:04 - Approaching human performance limits and societal health impacts13:48 - Early discoveries: microbiome sampling from Boston Marathon runners27:19 - The breakthrough finding: Vianella's role in fatigue and endurance30:19 - Scientific steps to isolate and validate Vianella33:29 - Regulatory considerations for microbiome supplements versus therapeutics36:04 - Prevalence of Vianella across different athletes and individuals40:51 - Microbiome as a dynamic, modifiable biomarker for health and sport45:37 - Metabolism, mitochondria, and longevity interconnected through microbiome dynamics49:16 - Influences of science fiction on biotech imagination and vision57:39 - Future applications: wearables, continuous monitoring, and AI in microbiome health1:00:46 - Vision for FitBiomics’ role in health innovation and societal impact
Transcribe →Yuanhao Qu: Programming Biology with AI
Mar 1601:01:11Tap to summarizeBiology is becoming programmable.In this episode of Galaxy Balance, Cory Smith speaks with Yuanhao Qu, President and Co-Founder of PhyloBio, about the emergence of AI driven biological discovery. Yuanhao represents a new generation of scientists who combine genome engineering with large language models to build systems that can reason about DNA and accelerate research across the life sciences.The conversation explores Yuanhao’s journey from early cancer research to developing CRISPR-GPT and Biomni, tools designed to help scientists design experiments, analyze data, and navigate the growing complexity of biological research. The discussion then moves to the founding of PhyloBio and the idea of an integrated biology environment where AI agents collaborate with human researchers.We examine the future of genome engineering, the challenges of delivering gene therapies, and how AI agents may soon assist in designing experiments, generating hypotheses, and exploring massive biological datasets. They also discuss the possibility of automated laboratories, the evolving role of scientists in an AI-augmented research ecosystem, and the ethical boundaries that must guide advances in synthetic biology.The episode closes with a discussion of science fiction, biosecurity, and the long term vision of AI systems that help humanity understand life at every scale.If biology becomes a language, the next frontier will belong to those who learn how to speak it.Phylo is a research lab developing cutting-edge agentic intelligence to accelerate discovery for biomedical scientists. They are building Biomni Lab, an integrated biology environment that leverages the latest AI to transform how biologists work. Explore it at biomni.phylo.bioPhylo is also actively hiring. Learn more at phylo.bio/careersTimestamps:00:00 - Embracing rapid change and AI tools in biology02:24 - Yuanhao’s background and motivation to cure cancer04:11 - Analyzing complex diseases with genomics and AI07:25 - Switching focus to AI-guided discovery and CRISPR engineering12:13 - Building and deploying CRISPR-GPT to democratize gene editing design16:23 - How AI enhances the role of scientists rather than replacing them20:52 - The story behind PhiloBio and its vision to accelerate biotech innovation24:01 - Developing BioOmni: an AI environment for biological research28:21 - The future of AI in autonomous labs and the challenge of human-in-the-loop systems36:33 - Ensuring safety and predicting oncogenic risk in genome engineering42:49 - Advances needed in delivery mechanisms for gene therapies45:02 - Insights into human intelligence evolution and AI’s role in discovery51:04 - The significance of memory, personalization, and continuous learning in AI agents55:06 - Ethical dilemmas in human germline modification and societal impacts58:30 - Speculations on life’s prevalence in the universe and the Dark Forest hypothesis59:46 - Advice for aspiring scientists eager to innovate with AI
Transcribe →Marc Güell: AI, Synthetic Evolution, and the Future of Genome Engineering
Mar 1001:05:14Tap to summarizeIn this episode of Galaxy Balance, Cory Smith is joined by Marc Güell, a synthetic biologist working at the frontier of genome engineering, AI-driven biological design, and translational therapeutics. Marc's work spans programmable genome integration systems, synthetic evolution, and the development of biological tools that extend far beyond what natural evolution has produced.From his early training in chemistry and engineering to his time in the Church Lab at Harvard and now leading a research group in Barcelona, Marc's career reflects a consistent focus on building new biological technologies. The conversation explores how generative AI is reshaping genome writing, why engineering principles matter in biology, and what it takes to translate deep-tech synthetic biology into real-world applications.We also discuss the founding of Integra Therapeutics, engineering the skin microbiome as a therapeutic platform, and how imagination influences real life science.00:00 - How AI enables exploration of unconstrained genotypical spaces in synthetic biology02:18 - Dr. Guell’s childhood in the Pyrenees fueling his passion for building and discovery03:14 - From organic chemistry to synthetic genome engineering at Heidelberg and Harvard05:33 - Recent advances in genome editing: CRISPR, xenotransplantation, and deep tech biotech startups09:48 - The coming revolution: speaking DNA with AI tools and designing complex genetic circuits12:30 - Navigating the vast, unconstrained genetic landscape using synthesis-free, AI-guided methods15:44 - Exploring the complexity of splicing, gene regulation, and the role of AI in modeling biological systems20:31 - Improving protein design and gene writing with coupled CRISPR and transposases22:58 - Using AI-generated transposases surpassing natural biodiversity and expanding genotypic networks27:09 - Strategies for safe, targeted insertions in gene therapy and cell engineering safety sites30:20 - The mission of Integrate Therapeutics: commercializing AI-driven transposon technologies for cell therapies34:50 - Challenges facing biotech startups and the need for strategic, cautious growth39:42 - Engineering skin microbiomes for health and aesthetic applications, from acne to inflammation sensing44:38 - The incredible potential of microbiome modulation for systemic health and space travel applications46:46 - Ethical and safety considerations for AI-designed proteins and synthetic biology innovations49:48 - Cross-cultural perspectives in science: Europe, the US, and China’s unique approaches and collaboration opportunities51:59 - Automation and AI in experimental biology: new paradigms for high-throughput, in-silico evolution55:18 - The impact of AI assistants and knowledge agents in accelerating scientific discovery59:20 - The influence of science fiction: predicting and inspiring future biotechnologies1:01:23 - Contemplating the nature of life, complexity, and the role of AI in understanding biology’s mysteries1:04:25 - The power of imagination and science fiction in shaping the next generation of biotech breakthroughs
Transcribe →